{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:18:01Z","timestamp":1759936681433},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T00:00:00Z","timestamp":1302652800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1007\/s10456-011-9212-6","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T12:33:07Z","timestamp":1302611587000},"page":"281-291","source":"Crossref","is-referenced-by-count":27,"title":["Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases"],"prefix":"10.1007","volume":"14","author":[{"given":"Johanna","family":"Liebl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Krystof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Vereb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Tak\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Strnad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Pechan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libor","family":"Havlicek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Zatloukal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"F\u00fcrst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika M.","family":"Vollmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zahler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,13]]},"reference":[{"key":"9212_CR1","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1038\/sj.onc.1206954","volume":"22","author":"AM Senderowicz","year":"2003","unstructured":"Senderowicz AM (2003) Small-molecule cyclin-dependent kinase modulators. Oncogene 22:6609\u20136620","journal-title":"Oncogene"},{"key":"9212_CR2","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.ceb.2004.09.014","volume":"16","author":"AM Senderowicz","year":"2004","unstructured":"Senderowicz AM (2004) Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 16:670\u2013678","journal-title":"Curr Opin Cell Biol"},{"key":"9212_CR3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","volume":"243","author":"L Meijer","year":"1997","unstructured":"Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243:527\u2013536","journal-title":"Eur J Biochem"},{"key":"9212_CR4","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0968-0896(99)00064-4","volume":"7","author":"M Legraverend","year":"1999","unstructured":"Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L, Giocanti N, Sadri R, Favaudon V (1999) Synthesis and in vitro evaluation of novel 2, 6, 9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorg Med Chem 7:1281\u20131293","journal-title":"Bioorg Med Chem"},{"key":"9212_CR5","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1016\/S0960-894X(02)00693-5","volume":"12","author":"V Krystof","year":"2002","unstructured":"Krystof V, Lenobel R, Havlicek L, Kuzma M, Strnad M (2002) Synthesis and biological activity of olomoucine II. Bioorg Med Chem Lett 12:3283\u20133286","journal-title":"Bioorg Med Chem Lett"},{"key":"9212_CR6","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00018-005-5185-1","volume":"62","author":"V Krystof","year":"2005","unstructured":"Krystof V, McNae IW, Walkinshaw MD, Fischer PM, Muller P, Vojtesek B, Orsag M, Havlicek L, Strnad M (2005) Antiproliferative activity of olomoucine II, a novel 2, 6, 9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci 62:1763\u20131771","journal-title":"Cell Mol Life Sci"},{"key":"9212_CR7","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1517\/13543780903418445","volume":"18","author":"IT Aldoss","year":"2009","unstructured":"Aldoss IT, Tashi T, Ganti AK (2009) Seliciclib in malignancies. Expert Opin Investig Drugs 18:1957\u20131965","journal-title":"Expert Opin Investig Drugs"},{"key":"9212_CR8","first-page":"1311","volume":"5","author":"T Guzi","year":"2004","unstructured":"Guzi T (2004) CYC-202 Cyclacel. Curr Opin Investig Drugs 5:1311\u20131318","journal-title":"Curr Opin Investig Drugs"},{"key":"9212_CR9","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1038\/sj.onc.1206816","volume":"22","author":"T Tonini","year":"2003","unstructured":"Tonini T, Rossi F, Claudio PP (2003) Molecular basis of angiogenesis and cancer. Oncogene 22:6549\u20136556","journal-title":"Oncogene"},{"key":"9212_CR10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592\u2013603","journal-title":"Nat Rev Cancer"},{"key":"9212_CR11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejmech.2005.12.004","volume":"41","author":"AH Abadi","year":"2006","unstructured":"Abadi AH, Abou-Seri SM, Abdel-Rahman DE, Klein C, Lozach O, Meijer L (2006) Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents. Eur J Med Chem 41:296\u2013305","journal-title":"Eur J Med Chem"},{"key":"9212_CR12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2184.2008.00570.x","volume":"42","author":"L Maggiorella","year":"2009","unstructured":"Maggiorella L, Aubel C, Haton C, Milliat F, Connault E, Opolon P, Deutsch E, Bourhis J (2009) Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma. Cell Prolif 42:38\u201348","journal-title":"Cell Prolif"},{"key":"9212_CR13","doi-asserted-by":"crossref","unstructured":"Zahler S, Liebl J, Furst R, Vollmar AM (2010) Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro. Angiogenesis","DOI":"10.1007\/s10456-010-9181-1"},{"key":"9212_CR14","doi-asserted-by":"crossref","unstructured":"Liebl J, Weitensteiner SB, Vereb G, Takacs L, F\u00fcerst R, Vollmar AM, Zahler S (2010) Cyclin dependent kinase 5 (Cdk5) regulates endothelial cell migration and angiogenesis. J Biol Chem","DOI":"10.1074\/jbc.M110.126177"},{"key":"9212_CR15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1021\/jm960666x","volume":"40","author":"L Havlicek","year":"1997","unstructured":"Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, Strnad M (1997) Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 40:408\u2013412","journal-title":"J Med Chem"},{"key":"9212_CR16","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1021\/jm990506w","volume":"43","author":"M Otyepka","year":"2000","unstructured":"Otyepka M, Krystof V, Havlicek L, Siglerova V, Strnad M, Koca J (2000) Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J Med Chem 43:2506\u20132513","journal-title":"J Med Chem"},{"key":"9212_CR17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.281.5376.533","volume":"281","author":"NS Gray","year":"1998","unstructured":"Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L et al (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533\u2013538","journal-title":"Science"},{"key":"9212_CR18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.RES.0000017068.58856.F3","volume":"90","author":"AK Kiemer","year":"2002","unstructured":"Kiemer AK, Weber NC, F\u00fcrst R, Bildner N, Kulhanek-Heinze S, Vollmar AM (2002) Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circ Res 90:874\u2013881","journal-title":"Circ Res"},{"key":"9212_CR19","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/j.1582-4934.2008.00561.x","volume":"13","author":"A Koltermann","year":"2009","unstructured":"Koltermann A, Liebl J, F\u00fcrst R, Ammer H, Vollmar AM, Zahler S (2009) Ginkgo biloba extract EGb 761 exerts anti-angiogenic effects via activation of tyrosine phosphatases. J Cell Mol Med 13:2122\u20132130","journal-title":"J Cell Mol Med"},{"key":"9212_CR20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","volume":"139","author":"I Nicoletti","year":"1991","unstructured":"Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271\u2013279","journal-title":"J Immunol Methods"},{"key":"9212_CR21","first-page":"1625","volume":"37","author":"BM Kenyon","year":"1996","unstructured":"Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D\u2019Amato RJ (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37:1625\u20131632","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9212_CR22","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood-2002-12-3634","volume":"102","author":"T Licht","year":"2003","unstructured":"Licht T, Tsirulnikov L, Reuveni H, Yarnitzky T, Ben-Sasson SA (2003) Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). Blood 102:2099\u20132107","journal-title":"Blood"},{"key":"9212_CR23","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","volume":"243","author":"WF Azevedo De","year":"1997","unstructured":"De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243:518\u2013526","journal-title":"Eur J Biochem"},{"key":"9212_CR24","doi-asserted-by":"crossref","first-page":"31208","DOI":"10.1074\/jbc.M500806200","volume":"280","author":"S Bach","year":"2005","unstructured":"Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, Koken M, Coburn SP, Tang L, Jiang T et al (2005) Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 280:31208\u201331219","journal-title":"J Biol Chem"},{"key":"9212_CR25","doi-asserted-by":"crossref","first-page":"e12117","DOI":"10.1371\/journal.pone.0012117","volume":"5","author":"B Menn","year":"2010","unstructured":"Menn B, Bach S, Blevins TL, Campbell M, Meijer L, Timsit S (2010) Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One 5:e12117","journal-title":"PLoS One"},{"key":"9212_CR26","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1158\/0008-5472.CAN-09-1107","volume":"70","author":"G Feldmann","year":"2010","unstructured":"Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, Goggins M, Maitra A, Nelkin BD (2010) Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 70:4460\u20134469","journal-title":"Cancer Res"},{"key":"9212_CR27","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1158\/0008-5472.CAN-05-3048","volume":"66","author":"CJ Strock","year":"2006","unstructured":"Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD (2006) Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 66:7509\u20137515","journal-title":"Cancer Res"},{"key":"9212_CR28","doi-asserted-by":"crossref","unstructured":"Liu JL, Wang XY, Huang BX, Zhu F, Zhang RG, Wu G (2010) Expression of CDK5\/p35 in resected patients with non-small cell lung cancer: relation to prognosis. Med Oncol","DOI":"10.1007\/s12032-010-9510-7"},{"key":"9212_CR29","first-page":"300","volume":"24","author":"J Liu","year":"2008","unstructured":"Liu J, Zhang DL, Shan SG (2008) Expression and clinical significance of cyclin H and CDK7 in human hemangiomas. Zhonghua Zheng Xing Wai Ke Za Zhi 24:300\u2013302","journal-title":"Zhonghua Zheng Xing Wai Ke Za Zhi"},{"key":"9212_CR30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/cvr\/cvp106","volume":"83","author":"N Wagner","year":"2009","unstructured":"Wagner N, Jehl-Pietri C, Lopez P, Murdaca J, Giordano C, Schwartz C, Gounon P, Hatem SN, Grimaldi P, Wagner KD (2009) Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc Res 83:61\u201371","journal-title":"Cardiovasc Res"},{"key":"9212_CR31","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1158\/0008-5472.CAN-09-0301","volume":"69","author":"S Ali","year":"2009","unstructured":"Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M et al (2009) The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res 69:6208\u20136215","journal-title":"Cancer Res"},{"key":"9212_CR32","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1242\/jcs.02718","volume":"118","author":"RP Fisher","year":"2005","unstructured":"Fisher RP (2005) Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 118:5171\u20135180","journal-title":"J Cell Sci"},{"key":"9212_CR33","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.4161\/cc.8.22.9890","volume":"8","author":"J Pirngruber","year":"2009","unstructured":"Pirngruber J, Shchebet A, Johnsen SA (2009) Insights into the function of the human P-TEFb component CDK9 in the regulation of chromatin modifications and co-transcriptional mRNA processing. Cell Cycle 8:3636\u20133642","journal-title":"Cell Cycle"},{"key":"9212_CR34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/138945010790711950","volume":"11","author":"V Krystof","year":"2010","unstructured":"Krystof V, Uldrijan S (2010) Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 11:291\u2013302","journal-title":"Curr Drug Targets"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-011-9212-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10456-011-9212-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-011-9212-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T23:46:43Z","timestamp":1560124003000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10456-011-9212-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,13]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["9212"],"URL":"https:\/\/doi.org\/10.1007\/s10456-011-9212-6","relation":{},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"value":"0969-6970","type":"print"},{"value":"1573-7209","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,13]]}}}